Problems grow for neuromodulation firm Helius Medical Technologies

By SharpBrains | February 15, 2019

Investor Alert: Kaplan Fox Inves­ti­gates Helius Med­ical Tech­nolo­gies, Inc. (press release): “NEW YORK, Feb. 7, 2019 /PRNewswire/ — Kaplan Fox & Kil­sheimer LLP has been inves­ti­gat­ing claims on behalf of investors of Helius Med­ical Tech­nologiues, Inc. (“Helius” or the “Com­pa­ny”) (Nas­daq: HSDT). On Jan­u­ary 22, 2019, after the mar­ket opened, White Dia­mond Research published

Read More

Helius Medical and HealthTech Connex partner to develop neuroplasticity clinics in Canada

By SharpBrains | October 3, 2018

___ Helius Med­ical Tech­nolo­gies and HealthTech Con­nex Announce Alliance to Build Cana­di­an Com­mer­cial Infra­struc­ture (press release): “Helius Med­ical Tech­nolo­gies, Inc. (NASDAQ:HSDT) (TSX:HSM), a neu­rotech com­pa­ny focused on neu­ro­log­i­cal well­ness, today announced that the Com­pa­ny has entered into an agree­ment with HealthTech Con­nex, Inc. (“HTC”) to devel­op and man­age neu­ro­plas­tic­i­ty clin­ics in Canada.

Read More